董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Scott F. Drees | 男 | President, Chief Executive Officer and Director | 58 | 27.21万美元 | 未持股 | 2016-02-22 |
| Kenneth G. Hawari | 男 | Director | 57 | 未披露 | 未持股 | 2016-02-22 |
| Thomas E. Zelibor | 男 | Director | 61 | 未披露 | 未持股 | 2016-02-22 |
| Fred B. Parks | 男 | Director | 68 | 未披露 | 未持股 | 2016-02-22 |
| Jon T. Tremmel | 男 | Director | 69 | 未披露 | 未持股 | 2016-02-22 |
| Joseph A. Miller, Jr. | 男 | Chairman of the Board | 74 | 未披露 | 未持股 | 2016-02-22 |
| Anthony P. Bihl III | 男 | Director | 59 | 未披露 | 未持股 | 2016-02-22 |
| David D. Johnson | 男 | Director | 60 | 未披露 | 未持股 | 2016-02-22 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Scott F. Drees | 男 | President, Chief Executive Officer and Director | 58 | 27.21万美元 | 未持股 | 2016-02-22 |
| Walter Z. Berger | 男 | Executive Vice President and Chief Financial Officer | 60 | 21.92万美元 | 未持股 | 2016-02-22 |
董事简历
中英对照 | 中文 | 英文- Scott F. Drees
-
Scott F. Drees将会担任Nuvectra总裁、首席执行官和董事。以全职身份加入Nuvectra之前，Drees自2009年8月起担任Nuvectra 以及子公司Algostim and PelviStim顾问。此外，Drees从2008年1月到2015年7月担任Neuromodulation Ventures, LLC总裁和首席执行官，专注于新型神经调节公司的培育。在医疗设备行业任职的34年期间，Drees担任过多个执行职位，包括担任Advanced Neuromodulation Systems, Inc., or ANS（一家神经调节公司，2005年被St. Jude Medical, Inc., or St. Jude Medical收购）创立部门总裁，全球销售和营销执行副总裁；还曾在 St. Jude Medical, Boston Scientific Corporation and Johnson & Johnson&'s Codman Neuro分部担任多个其他职位。Drees现任Neuros Medical, Inc.（一家私营神经调节公司）董事以及National Pain Foundation创始董事。Drees持有费城St. Joseph's University理学学士学位。Drees因其对公司业务的丰富知识、神经调节行业丰富的经验以及担任公司总裁和首席执行官的经验，被选为公司董事。
Scott F. Drees will serve as President, Chief Executive Officer and as a director of Nuvectra. Prior to joining Nuvectra on a full time basis, Mr. Drees served as a consultant to Nuvectra and our subsidiaries Algostim and PelviStim since August 2009. In addition, from January 2008 to July 2015 Mr. Drees also served as President and Chief Executive Officer of Neuromodulation Ventures, LLC, which focused on incubating new neuromodulation companies. Previously in his thirty-four year career in the medical device industry, Mr. Drees served in various executive positions, including, founding division President and, later, Executive Vice President, Worldwide Sales and Marketing, at Advanced Neuromodulation Systems, Inc., or ANS, a neuromodulation company that was acquired by St. Jude Medical, Inc., or St. Jude Medical, in 2005 and also various other positions at St. Jude Medical, Boston Scientific Corporation and Johnson & Johnson’s Codman Neuro division. Mr. Drees currently serves as a director of Neuros Medical, Inc., a privately-held neuromodulation company and was a founding board member of the National Pain Foundation. Mr. Drees earned a B.S. from St. Joseph’s University in Philadelphia. Mr. Drees has been selected to serve as a director on our Board of Directors due to his in-depth knowledge of our business, extensive experience in the neuromodulation industry and role as our President and Chief Executive Officer. - Scott F. Drees将会担任Nuvectra总裁、首席执行官和董事。以全职身份加入Nuvectra之前，Drees自2009年8月起担任Nuvectra 以及子公司Algostim and PelviStim顾问。此外，Drees从2008年1月到2015年7月担任Neuromodulation Ventures, LLC总裁和首席执行官，专注于新型神经调节公司的培育。在医疗设备行业任职的34年期间，Drees担任过多个执行职位，包括担任Advanced Neuromodulation Systems, Inc., or ANS（一家神经调节公司，2005年被St. Jude Medical, Inc., or St. Jude Medical收购）创立部门总裁，全球销售和营销执行副总裁；还曾在 St. Jude Medical, Boston Scientific Corporation and Johnson & Johnson&'s Codman Neuro分部担任多个其他职位。Drees现任Neuros Medical, Inc.（一家私营神经调节公司）董事以及National Pain Foundation创始董事。Drees持有费城St. Joseph's University理学学士学位。Drees因其对公司业务的丰富知识、神经调节行业丰富的经验以及担任公司总裁和首席执行官的经验，被选为公司董事。
- Scott F. Drees will serve as President, Chief Executive Officer and as a director of Nuvectra. Prior to joining Nuvectra on a full time basis, Mr. Drees served as a consultant to Nuvectra and our subsidiaries Algostim and PelviStim since August 2009. In addition, from January 2008 to July 2015 Mr. Drees also served as President and Chief Executive Officer of Neuromodulation Ventures, LLC, which focused on incubating new neuromodulation companies. Previously in his thirty-four year career in the medical device industry, Mr. Drees served in various executive positions, including, founding division President and, later, Executive Vice President, Worldwide Sales and Marketing, at Advanced Neuromodulation Systems, Inc., or ANS, a neuromodulation company that was acquired by St. Jude Medical, Inc., or St. Jude Medical, in 2005 and also various other positions at St. Jude Medical, Boston Scientific Corporation and Johnson & Johnson’s Codman Neuro division. Mr. Drees currently serves as a director of Neuros Medical, Inc., a privately-held neuromodulation company and was a founding board member of the National Pain Foundation. Mr. Drees earned a B.S. from St. Joseph’s University in Philadelphia. Mr. Drees has been selected to serve as a director on our Board of Directors due to his in-depth knowledge of our business, extensive experience in the neuromodulation industry and role as our President and Chief Executive Officer.
- Kenneth G. Hawari
-
Kenneth G. Hawari将会担任Nuvectra董事。Hawari自2007年起担任私人实践处律师和业务顾问。Hawari从2002年2月到2006年12月担任ANS企业开发执行副总裁和总法律顾问。加入ANS之前，Hawari从1984年到2002年担任Hughes & Luce LLP （后成为K&L Gates LLP一部分）律师。Hawari现任North Texas Enterprise Center for Technology, Inc.（一家非盈利组织，协助和培育医疗和其他技术公司）董事长。Hawari持有奥斯汀the University of Texas文学学士学位和法律博士学位。
Kenneth G. Hawari will serve as a director of Nuvectra. Since 2007 Mr. Hawari has worked as an attorney and business consultant in private practice. From February 2002 until December 2006 Mr. Hawari was Executive Vice President - Corporate Development and General Counsel for ANS. Prior to joining ANS, Mr. Hawari was an attorney at Hughes & Luce LLP which subsequently became part of K&L Gates LLP from 1984 until 2002. Mr. Hawari currently serves as the chairman of the board for the North Texas Enterprise Center for Technology, Inc., which is a not-for-profit organization that assists and incubates medical and other technology based companies. Mr. Hawari earned his B.A. and a J.D. each from the University of Texas at Austin. - Kenneth G. Hawari将会担任Nuvectra董事。Hawari自2007年起担任私人实践处律师和业务顾问。Hawari从2002年2月到2006年12月担任ANS企业开发执行副总裁和总法律顾问。加入ANS之前，Hawari从1984年到2002年担任Hughes & Luce LLP （后成为K&L Gates LLP一部分）律师。Hawari现任North Texas Enterprise Center for Technology, Inc.（一家非盈利组织，协助和培育医疗和其他技术公司）董事长。Hawari持有奥斯汀the University of Texas文学学士学位和法律博士学位。
- Kenneth G. Hawari will serve as a director of Nuvectra. Since 2007 Mr. Hawari has worked as an attorney and business consultant in private practice. From February 2002 until December 2006 Mr. Hawari was Executive Vice President - Corporate Development and General Counsel for ANS. Prior to joining ANS, Mr. Hawari was an attorney at Hughes & Luce LLP which subsequently became part of K&L Gates LLP from 1984 until 2002. Mr. Hawari currently serves as the chairman of the board for the North Texas Enterprise Center for Technology, Inc., which is a not-for-profit organization that assists and incubates medical and other technology based companies. Mr. Hawari earned his B.A. and a J.D. each from the University of Texas at Austin.
- Thomas E. Zelibor
-
Thomas E. Zelibor将会担任Nuvectra董事。Zelibor自2012年5月起担任Lightwave Logic（一家公开上市公司，专注于电光器件薄膜聚合物在电信和数据市场的应用）首席执行官和董事长。被任命为首席执行官之前，他从2008年7月到2012年4月担任Lightwave Logic董事。Zelibor从2011年4月到2012年4月担任私人管理顾问，2008年7月到2011年4月担任Flatirons Solutions Corp.（一家专业服务和系统工程公司）总裁和首席执行官。Zelibor还曾担任罗德岛新港Naval War College运营和战略领导学院院长职位，负责Professional Military Education的高级领导开发、个性发展和道德。加入私人部门之前，Zelibor获得美国海军少将军衔，还曾担任多个高级职位，包括Carrier Group Three, Navy CIO 指挥官；United States Strategic Command全球运营主管。Zelibor持有United States Naval Academy学士学位；是 Zell Center for Risk Research at the Kellogg School of Management, Northwestern University高级领导住宅项目参与者和客座学者。
Thomas E. Zelibor will serve as a director of Nuvectra. Since May 2012 Mr. Zelibor has been the Chief Executive Officer and Chairman of the Board of Lightwave Logic, a publicly traded company focused on utilizing thin film polymers for electro-optic devices employed in the telecom and datacom markets. Prior to being appointed as Chief Executive Officer, he served as a director for Lightwave Logic from July 2008 to April 2012. From April 2011 to April 2012 Mr. Zelibor was a private management consultant and from July 2008 to April 2011 was President and Chief Executive Officer of Flatirons Solutions Corp., a professional services and system engineering company. Mr. Zelibor also held the position of Dean, College of Operational and Strategic Leadership at the Naval War College in Newport, Rhode Island where he was responsible for senior leadership development, character development, and ethics for Professional Military Education. Prior to joining the private sector, Mr. Zelibor achieved the rank of Rear Admiral in the U.S. Navy and served in numerous senior positions, including Commander, Carrier Group Three, Navy CIO and Director of Global Operations, United States Strategic Command. Mr. Zelibor earned his bachelor’s degree from the United States Naval Academy and has been a participant in the Senior Leader in Residence Program and a visiting scholar for the Zell Center for Risk Research at the Kellogg School of Management, Northwestern University. - Thomas E. Zelibor将会担任Nuvectra董事。Zelibor自2012年5月起担任Lightwave Logic（一家公开上市公司，专注于电光器件薄膜聚合物在电信和数据市场的应用）首席执行官和董事长。被任命为首席执行官之前，他从2008年7月到2012年4月担任Lightwave Logic董事。Zelibor从2011年4月到2012年4月担任私人管理顾问，2008年7月到2011年4月担任Flatirons Solutions Corp.（一家专业服务和系统工程公司）总裁和首席执行官。Zelibor还曾担任罗德岛新港Naval War College运营和战略领导学院院长职位，负责Professional Military Education的高级领导开发、个性发展和道德。加入私人部门之前，Zelibor获得美国海军少将军衔，还曾担任多个高级职位，包括Carrier Group Three, Navy CIO 指挥官；United States Strategic Command全球运营主管。Zelibor持有United States Naval Academy学士学位；是 Zell Center for Risk Research at the Kellogg School of Management, Northwestern University高级领导住宅项目参与者和客座学者。
- Thomas E. Zelibor will serve as a director of Nuvectra. Since May 2012 Mr. Zelibor has been the Chief Executive Officer and Chairman of the Board of Lightwave Logic, a publicly traded company focused on utilizing thin film polymers for electro-optic devices employed in the telecom and datacom markets. Prior to being appointed as Chief Executive Officer, he served as a director for Lightwave Logic from July 2008 to April 2012. From April 2011 to April 2012 Mr. Zelibor was a private management consultant and from July 2008 to April 2011 was President and Chief Executive Officer of Flatirons Solutions Corp., a professional services and system engineering company. Mr. Zelibor also held the position of Dean, College of Operational and Strategic Leadership at the Naval War College in Newport, Rhode Island where he was responsible for senior leadership development, character development, and ethics for Professional Military Education. Prior to joining the private sector, Mr. Zelibor achieved the rank of Rear Admiral in the U.S. Navy and served in numerous senior positions, including Commander, Carrier Group Three, Navy CIO and Director of Global Operations, United States Strategic Command. Mr. Zelibor earned his bachelor’s degree from the United States Naval Academy and has been a participant in the Senior Leader in Residence Program and a visiting scholar for the Zell Center for Risk Research at the Kellogg School of Management, Northwestern University.
- Fred B. Parks
-
Fred B. Parks，他担任NDS外科成像公司（先进的医疗可视化技术提供商）的行政总裁及董事从2011年至2013。他曾担任Urologix的董事会主席及行政总裁从2003至2008年。在加入Urologix前，他担任马可尼医疗系统（医疗成像设备的多模态供应商）的总裁兼首席执行官，后来该公司被皇家飞利浦电子收购，使其融入飞利浦医疗业务。此前，他担任圣犹达医疗用品公司（一家医疗设备公司，专注于植入式心血管产品）的总裁，首席营运官及董事会成员，并担任EG＆G公司（现在为珀金埃尔默，一家多元化的科技公司）总裁，首席营运官及董事会成员。除了他过去服务于NDS，Urologix，EG＆G，和圣犹达医疗的董事会，他还服务于稳态成像有限责任公司（一家私人持有的磁共振成像技术开发商）的董事会从2010年到2011。他的资历包括他的丰富工作经验，为一些科技公司的高级管理人员和董事会成员，特别是在医疗设备和医疗成像等行业。
Fred B. Parks has been our President and Chief Executive Officer since October 31 2016. Dr. Parks was the Executive Chairman and Chief Executive Officer of Enovate Medical, from 2015 to October 2016. Dr. Parks served as Chief Executive Officer and Director of NDS Surgical Imaging, Inc., a provider of advanced medical visualization technology, from 2011 to 2013 and was Chairman of the Board and Chief Executive Officer of Urologix, Inc. from 2003 to 2008. Prior to joining Urologix, Dr. Parks served as President and Chief Executive Officer of Marconi Medical Systems, a multi-modality supplier of medical imaging equipment, and following its acquisition by Royal Philips Electronics, led its integration into the Philips medical business. Previously, Dr. Parks held positions as President, Chief Operating Officer, and board member of St. Jude Medical, Inc., a medical device company focusing on implantable cardiovascular products, and as President, Chief Operating Officer, and board member of EG&G, Inc. now PerkinElmer, a diversified technology company.Dr. Parks became a Director of NuVectra Corporation, which is focused on the development and commercialization of neurostimulation technology, in March 2016. In addition to his past service on the boards of NDS, Urologix, EG&G, and St. Jude Medical, Dr. Parks served on the board of Steady State Imaging, LLC, a privately held developer of specialized magnetic resonance imaging technology, from 2010 to 2011.Dr. Parks’ qualifications include his substantial experience as a senior executive and board member for a number of technology companies, and particularly in the medical device and medical imaging industries. As President and Chief Executive Officer of Analogic, his in-depth knowledge of our Company provides our board with additional insight in areas such as strategic planning, financial and budgeting matters, engineering and product development, operations, sales and marketing, general management and other areas impacting our Company and its operations. - Fred B. Parks，他担任NDS外科成像公司（先进的医疗可视化技术提供商）的行政总裁及董事从2011年至2013。他曾担任Urologix的董事会主席及行政总裁从2003至2008年。在加入Urologix前，他担任马可尼医疗系统（医疗成像设备的多模态供应商）的总裁兼首席执行官，后来该公司被皇家飞利浦电子收购，使其融入飞利浦医疗业务。此前，他担任圣犹达医疗用品公司（一家医疗设备公司，专注于植入式心血管产品）的总裁，首席营运官及董事会成员，并担任EG＆G公司（现在为珀金埃尔默，一家多元化的科技公司）总裁，首席营运官及董事会成员。除了他过去服务于NDS，Urologix，EG＆G，和圣犹达医疗的董事会，他还服务于稳态成像有限责任公司（一家私人持有的磁共振成像技术开发商）的董事会从2010年到2011。他的资历包括他的丰富工作经验，为一些科技公司的高级管理人员和董事会成员，特别是在医疗设备和医疗成像等行业。
- Fred B. Parks has been our President and Chief Executive Officer since October 31 2016. Dr. Parks was the Executive Chairman and Chief Executive Officer of Enovate Medical, from 2015 to October 2016. Dr. Parks served as Chief Executive Officer and Director of NDS Surgical Imaging, Inc., a provider of advanced medical visualization technology, from 2011 to 2013 and was Chairman of the Board and Chief Executive Officer of Urologix, Inc. from 2003 to 2008. Prior to joining Urologix, Dr. Parks served as President and Chief Executive Officer of Marconi Medical Systems, a multi-modality supplier of medical imaging equipment, and following its acquisition by Royal Philips Electronics, led its integration into the Philips medical business. Previously, Dr. Parks held positions as President, Chief Operating Officer, and board member of St. Jude Medical, Inc., a medical device company focusing on implantable cardiovascular products, and as President, Chief Operating Officer, and board member of EG&G, Inc. now PerkinElmer, a diversified technology company.Dr. Parks became a Director of NuVectra Corporation, which is focused on the development and commercialization of neurostimulation technology, in March 2016. In addition to his past service on the boards of NDS, Urologix, EG&G, and St. Jude Medical, Dr. Parks served on the board of Steady State Imaging, LLC, a privately held developer of specialized magnetic resonance imaging technology, from 2010 to 2011.Dr. Parks’ qualifications include his substantial experience as a senior executive and board member for a number of technology companies, and particularly in the medical device and medical imaging industries. As President and Chief Executive Officer of Analogic, his in-depth knowledge of our Company provides our board with additional insight in areas such as strategic planning, financial and budgeting matters, engineering and product development, operations, sales and marketing, general management and other areas impacting our Company and its operations.
- Jon T. Tremmel
-
Jon T. Tremmel，2010年被选任为本公司董事。2007年4月从Medtronic退休后，他成为一名业务顾问；从2003年3月起，他担任该公司神经科部门总裁；2001年5月至2003年3月，担任生理控制部门总裁；1992-2001，他担任快速性心律失常管理与介入血管部门的总裁。自1978年加入Medtronic到1992年，他担任多个愈益重要的职务。目前，他是以下公司的董事和薪酬委员会成员：EnteroMedics，从事开发治疗肥胖症的神经刺激装置的上市公司；Flowonix Medical Incorporated，从事开发治疗慢性疼痛的植入泵的私营公司。
Jon T. Tremmel,has served as one of our directors since January 2009. Mr. Tremmel has been retired and acting as an independent consultant since 2007. Over the course of his career at Medtronic, Inc., Mr. Tremmel served in a variety of senior management positions, including President of the Neurological Division from 2003 to 2007 President of the Physio Control Division, President of the Tachyarrhythmia Management Division and President of the Interventional Vascular Division. Mr. Tremmel currently serves on the board of Cyberonics, Inc., a publicly-held company that designs, develops and markets implantable medical devices for the treatment of epilepsy and other debilitating neurological disorders and, Nuvectra Corp, a publically-held neuromodulation medical device company focused on the development of neurostimulation technology to treat various disorders of the nervous systems. - Jon T. Tremmel，2010年被选任为本公司董事。2007年4月从Medtronic退休后，他成为一名业务顾问；从2003年3月起，他担任该公司神经科部门总裁；2001年5月至2003年3月，担任生理控制部门总裁；1992-2001，他担任快速性心律失常管理与介入血管部门的总裁。自1978年加入Medtronic到1992年，他担任多个愈益重要的职务。目前，他是以下公司的董事和薪酬委员会成员：EnteroMedics，从事开发治疗肥胖症的神经刺激装置的上市公司；Flowonix Medical Incorporated，从事开发治疗慢性疼痛的植入泵的私营公司。
- Jon T. Tremmel,has served as one of our directors since January 2009. Mr. Tremmel has been retired and acting as an independent consultant since 2007. Over the course of his career at Medtronic, Inc., Mr. Tremmel served in a variety of senior management positions, including President of the Neurological Division from 2003 to 2007 President of the Physio Control Division, President of the Tachyarrhythmia Management Division and President of the Interventional Vascular Division. Mr. Tremmel currently serves on the board of Cyberonics, Inc., a publicly-held company that designs, develops and markets implantable medical devices for the treatment of epilepsy and other debilitating neurological disorders and, Nuvectra Corp, a publically-held neuromodulation medical device company focused on the development of neurostimulation technology to treat various disorders of the nervous systems.
- Joseph A. Miller, Jr.
-
Joseph A. Miller, Jr. 自2001年以来，担任Corning, Inc.的执行副总裁兼首席技术官，2012年4月退休。之前，从1999年至2001年担任E.I. DuPont de Nemours的高级副总裁，此前曾担任各种管理职务。他是Lightwave Logic。的董事。他是Dow Corning Corporation的前董事。
Joseph A. Miller, Jr. will serve as Chairman of the Board of Nuvectra. He currently serves as a director for Greatbatch and will step down from Greatbatch’s board of directors shortly before the completion of the spin-off. Dr. Miller also currently serves as a director of Lightwave Logic, Inc., or Lightwave Logic, and previously served as a director of Dow Corning Corporation. Dr. Miller retired in April 2012 as Executive Vice President and Chief Technology Officer for Corning Incorporated, a position in which he had served since 2001. Before joining Corning in 2001 he served as Senior Vice President of E.I. DuPont de Nemours from 1999 to 2001 and held various executive positions with that company prior to that time. Dr. Miller has significant research and development knowledge and experience gained through his positions at Corning and E.I. DuPont. - Joseph A. Miller, Jr. 自2001年以来，担任Corning, Inc.的执行副总裁兼首席技术官，2012年4月退休。之前，从1999年至2001年担任E.I. DuPont de Nemours的高级副总裁，此前曾担任各种管理职务。他是Lightwave Logic。的董事。他是Dow Corning Corporation的前董事。
- Joseph A. Miller, Jr. will serve as Chairman of the Board of Nuvectra. He currently serves as a director for Greatbatch and will step down from Greatbatch’s board of directors shortly before the completion of the spin-off. Dr. Miller also currently serves as a director of Lightwave Logic, Inc., or Lightwave Logic, and previously served as a director of Dow Corning Corporation. Dr. Miller retired in April 2012 as Executive Vice President and Chief Technology Officer for Corning Incorporated, a position in which he had served since 2001. Before joining Corning in 2001 he served as Senior Vice President of E.I. DuPont de Nemours from 1999 to 2001 and held various executive positions with that company prior to that time. Dr. Miller has significant research and development knowledge and experience gained through his positions at Corning and E.I. DuPont.
- Anthony P. Bihl III
-
Anthony P. Bihl III，自2013年12月起担任Bioventus, LLC（该公司开发、生产、并销售骨科治疗产品）的首席执行官兼管理董事会成员。自2011年6月至2012年6月，担任 American Medical Systems（Endo Pharmaceuticals的附属公司）的集团总裁。在此之前，从2008年4月至2011年6月Endo收购AMS，担任AMS的总裁兼首席执行官、董事。从2007年1月到11月，担任Siemens Medical Solutions的诊断部门的首席执行官。从2004年到2006年，担任Bayer HealthCare诊断部门的总裁。在这之前，曾在Bayer HealthCare担任多个业务和财务职位，并在E.I. DuPont工作20年。现任Spectral Diagnostics, Inc.（一家加拿大公司，开发严重败血症及感染性休克的诊断和治疗产品）的董事长、人力资源主席和薪酬委员会主席、审计委员会成员。他是SeraCare Life Sciences Inc.的前董事。
Anthony P. Bihl III,served as Chief Executive Officer and a member of the board of managers of Bioventus, LLC, a company that develops, manufactures and sells products that promote active orthopedic healing, from December 2013 to April 2020. From June 2011 through June 2012, he was Group President of American Medical Systems, or AMS, a subsidiary of Endo Pharmaceuticals. Mr. Bihl was President, Chief Executive Officer and a director of AMS from April 2008 until Endo acquired AMS in June 2011. He served as Chief Executive Officer of the Diagnostics Division of Siemens Medical Solutions from January to November 2007, and as President of the Diagnostics Division of Bayer HealthCare from 2004 through 2006. Prior to that, Mr. Bihl served in a number of operations and finance roles at Bayer HealthCare and for over 20 years at E.I. DuPont. Mr. Bihl is a director and Chairman of the Board of Spectral Medical, Inc. (TSX: EDTXF), a Canadian company that develops products for the diagnosis and treatment of severe sepsis and septic shock, and Sonendo, Inc. (NYSE:SONX), a leading dental technology company. Mr. Bihl previously served on the boards of directors of Flowonix Medical Inc., a privately held company that develops and markets targeted drug delivery platforms (July 2020 – March 2022); Nuvectra Corporation (OTC: NVTRQ) from March 2016 to May 2020; and prior to March 2016, Integer Holdings Corporation (NYSE: ITGR) before it spun off Nuvectra. - Anthony P. Bihl III，自2013年12月起担任Bioventus, LLC（该公司开发、生产、并销售骨科治疗产品）的首席执行官兼管理董事会成员。自2011年6月至2012年6月，担任 American Medical Systems（Endo Pharmaceuticals的附属公司）的集团总裁。在此之前，从2008年4月至2011年6月Endo收购AMS，担任AMS的总裁兼首席执行官、董事。从2007年1月到11月，担任Siemens Medical Solutions的诊断部门的首席执行官。从2004年到2006年，担任Bayer HealthCare诊断部门的总裁。在这之前，曾在Bayer HealthCare担任多个业务和财务职位，并在E.I. DuPont工作20年。现任Spectral Diagnostics, Inc.（一家加拿大公司，开发严重败血症及感染性休克的诊断和治疗产品）的董事长、人力资源主席和薪酬委员会主席、审计委员会成员。他是SeraCare Life Sciences Inc.的前董事。
- Anthony P. Bihl III,served as Chief Executive Officer and a member of the board of managers of Bioventus, LLC, a company that develops, manufactures and sells products that promote active orthopedic healing, from December 2013 to April 2020. From June 2011 through June 2012, he was Group President of American Medical Systems, or AMS, a subsidiary of Endo Pharmaceuticals. Mr. Bihl was President, Chief Executive Officer and a director of AMS from April 2008 until Endo acquired AMS in June 2011. He served as Chief Executive Officer of the Diagnostics Division of Siemens Medical Solutions from January to November 2007, and as President of the Diagnostics Division of Bayer HealthCare from 2004 through 2006. Prior to that, Mr. Bihl served in a number of operations and finance roles at Bayer HealthCare and for over 20 years at E.I. DuPont. Mr. Bihl is a director and Chairman of the Board of Spectral Medical, Inc. (TSX: EDTXF), a Canadian company that develops products for the diagnosis and treatment of severe sepsis and septic shock, and Sonendo, Inc. (NYSE:SONX), a leading dental technology company. Mr. Bihl previously served on the boards of directors of Flowonix Medical Inc., a privately held company that develops and markets targeted drug delivery platforms (July 2020 – March 2022); Nuvectra Corporation (OTC: NVTRQ) from March 2016 to May 2020; and prior to March 2016, Integer Holdings Corporation (NYSE: ITGR) before it spun off Nuvectra.
- David D. Johnson
-
David D. Johnson， 他是Molex公司的司库、首席财务官和执行副总裁（自2005年以来）。他负责Molex公司的全球金融业务，包括外部财务报告、会计、税务、财政、财务计划和分析、内部审计和投资者关系。他于2005年重新加入Molex公司。
David D. Johnson also served as a director of Nuvectra Corporation a neurostimulation medical device company from March 2016 to May 2020 and served as Chair of its Audit Committee. He previously served as Executive Vice President, Treasurer and Chief Financial Officer of Molex LLC (a manufacturer of electronic connectors and components) from 2005 to February 2016; Vice President, Treasurer and Chief Financial Officer of Sypris Solutions, Inc., from 1996 to 2005; Regional Controller for Molex’s Far East Region; Financial Director for New Ventures and Acquisitions; and Financial Director for the Far East South Region from 1984 to 1996. From 1978 to 1984 Mr. Johnson worked for the public accounting firm KPMG LLP. - David D. Johnson， 他是Molex公司的司库、首席财务官和执行副总裁（自2005年以来）。他负责Molex公司的全球金融业务，包括外部财务报告、会计、税务、财政、财务计划和分析、内部审计和投资者关系。他于2005年重新加入Molex公司。
- David D. Johnson also served as a director of Nuvectra Corporation a neurostimulation medical device company from March 2016 to May 2020 and served as Chair of its Audit Committee. He previously served as Executive Vice President, Treasurer and Chief Financial Officer of Molex LLC (a manufacturer of electronic connectors and components) from 2005 to February 2016; Vice President, Treasurer and Chief Financial Officer of Sypris Solutions, Inc., from 1996 to 2005; Regional Controller for Molex’s Far East Region; Financial Director for New Ventures and Acquisitions; and Financial Director for the Far East South Region from 1984 to 1996. From 1978 to 1984 Mr. Johnson worked for the public accounting firm KPMG LLP.
高管简历
中英对照 | 中文 | 英文- Scott F. Drees
Scott F. Drees将会担任Nuvectra总裁、首席执行官和董事。以全职身份加入Nuvectra之前，Drees自2009年8月起担任Nuvectra 以及子公司Algostim and PelviStim顾问。此外，Drees从2008年1月到2015年7月担任Neuromodulation Ventures, LLC总裁和首席执行官，专注于新型神经调节公司的培育。在医疗设备行业任职的34年期间，Drees担任过多个执行职位，包括担任Advanced Neuromodulation Systems, Inc., or ANS（一家神经调节公司，2005年被St. Jude Medical, Inc., or St. Jude Medical收购）创立部门总裁，全球销售和营销执行副总裁；还曾在 St. Jude Medical, Boston Scientific Corporation and Johnson & Johnson&'s Codman Neuro分部担任多个其他职位。Drees现任Neuros Medical, Inc.（一家私营神经调节公司）董事以及National Pain Foundation创始董事。Drees持有费城St. Joseph's University理学学士学位。Drees因其对公司业务的丰富知识、神经调节行业丰富的经验以及担任公司总裁和首席执行官的经验，被选为公司董事。
Scott F. Drees will serve as President, Chief Executive Officer and as a director of Nuvectra. Prior to joining Nuvectra on a full time basis, Mr. Drees served as a consultant to Nuvectra and our subsidiaries Algostim and PelviStim since August 2009. In addition, from January 2008 to July 2015 Mr. Drees also served as President and Chief Executive Officer of Neuromodulation Ventures, LLC, which focused on incubating new neuromodulation companies. Previously in his thirty-four year career in the medical device industry, Mr. Drees served in various executive positions, including, founding division President and, later, Executive Vice President, Worldwide Sales and Marketing, at Advanced Neuromodulation Systems, Inc., or ANS, a neuromodulation company that was acquired by St. Jude Medical, Inc., or St. Jude Medical, in 2005 and also various other positions at St. Jude Medical, Boston Scientific Corporation and Johnson & Johnson’s Codman Neuro division. Mr. Drees currently serves as a director of Neuros Medical, Inc., a privately-held neuromodulation company and was a founding board member of the National Pain Foundation. Mr. Drees earned a B.S. from St. Joseph’s University in Philadelphia. Mr. Drees has been selected to serve as a director on our Board of Directors due to his in-depth knowledge of our business, extensive experience in the neuromodulation industry and role as our President and Chief Executive Officer.- Scott F. Drees将会担任Nuvectra总裁、首席执行官和董事。以全职身份加入Nuvectra之前，Drees自2009年8月起担任Nuvectra 以及子公司Algostim and PelviStim顾问。此外，Drees从2008年1月到2015年7月担任Neuromodulation Ventures, LLC总裁和首席执行官，专注于新型神经调节公司的培育。在医疗设备行业任职的34年期间，Drees担任过多个执行职位，包括担任Advanced Neuromodulation Systems, Inc., or ANS（一家神经调节公司，2005年被St. Jude Medical, Inc., or St. Jude Medical收购）创立部门总裁，全球销售和营销执行副总裁；还曾在 St. Jude Medical, Boston Scientific Corporation and Johnson & Johnson&'s Codman Neuro分部担任多个其他职位。Drees现任Neuros Medical, Inc.（一家私营神经调节公司）董事以及National Pain Foundation创始董事。Drees持有费城St. Joseph's University理学学士学位。Drees因其对公司业务的丰富知识、神经调节行业丰富的经验以及担任公司总裁和首席执行官的经验，被选为公司董事。
- Scott F. Drees will serve as President, Chief Executive Officer and as a director of Nuvectra. Prior to joining Nuvectra on a full time basis, Mr. Drees served as a consultant to Nuvectra and our subsidiaries Algostim and PelviStim since August 2009. In addition, from January 2008 to July 2015 Mr. Drees also served as President and Chief Executive Officer of Neuromodulation Ventures, LLC, which focused on incubating new neuromodulation companies. Previously in his thirty-four year career in the medical device industry, Mr. Drees served in various executive positions, including, founding division President and, later, Executive Vice President, Worldwide Sales and Marketing, at Advanced Neuromodulation Systems, Inc., or ANS, a neuromodulation company that was acquired by St. Jude Medical, Inc., or St. Jude Medical, in 2005 and also various other positions at St. Jude Medical, Boston Scientific Corporation and Johnson & Johnson’s Codman Neuro division. Mr. Drees currently serves as a director of Neuros Medical, Inc., a privately-held neuromodulation company and was a founding board member of the National Pain Foundation. Mr. Drees earned a B.S. from St. Joseph’s University in Philadelphia. Mr. Drees has been selected to serve as a director on our Board of Directors due to his in-depth knowledge of our business, extensive experience in the neuromodulation industry and role as our President and Chief Executive Officer.
- Walter Z. Berger
Walter Z. Berger，他一直担任我们执行副总裁兼首席财务官（2008年6月以来）。从2006年到2008年，他曾担任CBS Corporation的高级管理职务，包括CBS Radio（从属于CBS Corporation）的执行副总裁、首席财务官。加入CBS Radio公司之前，他曾担任Emmis Communications公司的执行副总裁兼首席财务官，以及董事（从1999年到2005年）。从1996年到1997年，他曾担任LG&E Energy Corporation的执行副总裁兼首席财务官，并于1997年被提升为能源市场营销部门的集团总裁（直到1999年）。从1985年到1996年，他曾担任多种财务运营管理职务，涉及制造、服务和能源领域。他的审计职业生涯始于1977年任职Arthur Andersen公司。他持有马萨诸塞大学阿默斯特分校（the University of Massachusetts, Amherst）的工商管理学士学位。
Walter Z. Berger will serve as Executive Vice President and Chief Financial Officer of Nuvectra. Prior to joining Nuvectra, Mr. Berger served as Chief Financial Officer of AppDynamics Inc., a venture-backed next generation application intelligence company from October 2013 until March 2015. Prior to that, from 2012 until 2013 Mr. Berger was the Chief Financial Officer of private equity owned SoftLayer, a cloud computing company, which was acquired by IBM. From 2008 until 2012 he served as Chief Financial Officer at Leap Wireless International, Inc. NASDAQ. Mr. Berger has also served as Executive Vice President and Chief Financial Officer for each of CBS Radio, Inc. and for Emmis Communications Corporation (NASDAQ). From 1985 to 1999 Mr. Berger held a number of financial and operating management roles in the manufacturing, services and energy fields. Mr. Berger began his career at Arthur Andersen in 1977. Mr. Berger is a Certified Public Accountant and holds a B.A. in business administration from the University of Massachusetts, Amherst.- Walter Z. Berger，他一直担任我们执行副总裁兼首席财务官（2008年6月以来）。从2006年到2008年，他曾担任CBS Corporation的高级管理职务，包括CBS Radio（从属于CBS Corporation）的执行副总裁、首席财务官。加入CBS Radio公司之前，他曾担任Emmis Communications公司的执行副总裁兼首席财务官，以及董事（从1999年到2005年）。从1996年到1997年，他曾担任LG&E Energy Corporation的执行副总裁兼首席财务官，并于1997年被提升为能源市场营销部门的集团总裁（直到1999年）。从1985年到1996年，他曾担任多种财务运营管理职务，涉及制造、服务和能源领域。他的审计职业生涯始于1977年任职Arthur Andersen公司。他持有马萨诸塞大学阿默斯特分校（the University of Massachusetts, Amherst）的工商管理学士学位。
- Walter Z. Berger will serve as Executive Vice President and Chief Financial Officer of Nuvectra. Prior to joining Nuvectra, Mr. Berger served as Chief Financial Officer of AppDynamics Inc., a venture-backed next generation application intelligence company from October 2013 until March 2015. Prior to that, from 2012 until 2013 Mr. Berger was the Chief Financial Officer of private equity owned SoftLayer, a cloud computing company, which was acquired by IBM. From 2008 until 2012 he served as Chief Financial Officer at Leap Wireless International, Inc. NASDAQ. Mr. Berger has also served as Executive Vice President and Chief Financial Officer for each of CBS Radio, Inc. and for Emmis Communications Corporation (NASDAQ). From 1985 to 1999 Mr. Berger held a number of financial and operating management roles in the manufacturing, services and energy fields. Mr. Berger began his career at Arthur Andersen in 1977. Mr. Berger is a Certified Public Accountant and holds a B.A. in business administration from the University of Massachusetts, Amherst.